DrugPatentWatch Database Preview
MOZOBIL Drug Profile
Which patents cover Mozobil, and when can generic versions of Mozobil launch?
Mozobil is a drug marketed by Genzyme and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.
This drug has forty-one patent family members in twenty-six countries.
The generic ingredient in MOZOBIL is plerixafor. There are seven drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the plerixafor profile page.
Summary for MOZOBIL
| International Patents: | 41 |
| US Patents: | 2 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 88 |
| Clinical Trials: | 78 |
| Patent Applications: | 1,154 |
| Drug Prices: | Drug price information for MOZOBIL |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for MOZOBIL |
| DailyMed Link: | MOZOBIL at DailyMed |
Generic Entry Opportunity Date for MOZOBIL
Generic Entry Date for MOZOBIL*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
SOLUTION;SUBCUTANEOUS |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for MOZOBIL
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Stanford University | Phase 2 |
| David Loeb | Phase 1 |
| Jonsson Comprehensive Cancer Center | Phase 1 |
Recent Litigation for MOZOBIL
Identify potential future generic entrants
District Court Litigation
| Case Name | Date |
|---|---|
| Genzyme Corporation v. Fresenius Kabi USA, LLC | 2018-12-06 |
| Genzyme Corporation v. Gland Pharma Limited | 2018-07-19 |
| Genzyme Corporation v. Zydus Pharmaceuticals (USA) Inc. | 2016-06-29 |
Pharmacology for MOZOBIL
| Drug Class | Hematopoietic Stem Cell Mobilizer |
| Physiological Effect | Increased Hematopoietic Stem Cell Mobilization |
Synonyms for MOZOBIL
| 078P461 |
| 1-({4-[(1,4,8,11-tetraazacyclotetradecan-1-yl)methyl]phenyl}methyl)-1,4,8,11-tetraazacyclotetradecane |
| 1-[[4-(1,4,8,11-tetrazacyclotetradec-1-ylmethyl)phenyl]methyl]-1,4,8,11-tetrazacyclotetradecane |
| 1-{[4-(1,4,8,11-tetraazacyclotetradecan-1-ylmethyl)phenyl]methyl}-1,4,8,11-tetraazacyclotetradecane |
| 1,1'-[1,4-Phenylenebis(methylene)]bis-1,4,8,11-tetraazacyclotetradecane |
| 1,1'-[1,4-Phenylenebis(methylene)]bis[1,4,8,11-tetraazacyclotetradecane] |
| 1,1'-[1,4-Phenylenebis(methylene)]bis[1,4,8,11-tetraazacyclotetradecane] & Galanthus nivalis agglutinin (GNA) |
| 1,1'-[1,4-Phenylenebis(methylene)]bis[1,4,8,11-tetraazacyclotetradecane] & Hippeastrum hybrid agglutinin( HHA) |
| 1,1'-{1,4-phenylenebis(methylene)}-bis{1,4,8,11-tetraaza-cyclotetradecane} |
| 1,1''''-{1,4-phenylenebis(methylene)}-bis{1,4,8,11-tetraaza-cyclotetradecane} |
| 1,1'[1,4-phenylene-bis-(methylene)]-bis-1,4,8,11-tetraazacyclotetradecane |
| 1,4-Bis((1,4,8,11-tetraazacyclotetradecan-1-yl)methyl)benzene |
| 1,4,8,11-tetraazacyclotetradecanyl[4-(1,4,8,11-tetraazacyclotetradecanylmethyl)phenyl]methane |
| 1,4,8,11-tetraazacyclotetradecanyl[4-(1,4,8,11-tetraazacyclotetradecanylmethyl)phenyl]methane(8HBr.2H2O) |
| 11-{4-[4,8, 11-1,4,8,11tetraaza-cyclotetradec-1-ylmethyl]-benzyl}-1,4,8,11tetraaza-cyclotetradecane-1,4,8-tricarboxylic acid tri-tert-butyl ester |
| 11''''-xylyl bis-1,4,8,11-tetraazacyclotetradecane |
| 110078-46-1 |
| 4CA-1029 |
| A25446 |
| A809618 |
| AB0009909 |
| AB01566900_01 |
| AB1008451 |
| AC-26837 |
| AC1L22ET |
| AJ-81365 |
| AK-41732 |
| AKOS005266706 |
| Amd 3100 |
| AMD-3100 |
| AMD3100 |
| AMD3100 octahydrochloride |
| AN-436 |
| ANW-73610 |
| AOB5591 |
| AS-42504 |
| BC623053 |
| BCP02337 |
| BCPP000104 |
| BDBM50035696 |
| bicyclam JM-2987 |
| BRD-K33240821-367-01-8 |
| C28H54N8 |
| CHEBI:125354 |
| CHEMBL18442 |
| CS-0451 |
| CTK8C4952 |
| D08971 |
| DB06809 |
| EX-A1762 |
| FT-0660392 |
| GNA & AMD-3100 |
| GTPL844 |
| HHA & AMD-3100 |
| HY-10046 |
| I14-9461 |
| J-503718 |
| JKL 169 |
| JM 2987 |
| JM 3100 |
| JM 3100, AMD3100 |
| JM-3100 |
| JM3100 |
| KS-00000OBY |
| L000104 |
| LS-187299 |
| MolPort-009-019-417 |
| Mozobil (TN) |
| NCGC00165722-01 |
| NCGC00165722-02 |
| Plerixafor |
| plerixafor (amd3100) |
| Plerixafor (JAN/USAN/INN) |
| Plerixafor [USAN:INN:BAN] |
| Plerixafor-d4 (deuterated) |
| Plerixafor(AMD3100) |
| RL00426 |
| S-7677 |
| s8030 |
| S915P5499N |
| SC-21932 |
| SCHEMBL19038 |
| SDZ SID 791 |
| SID791 |
| SR-01000941593 |
| SR-01000941593-1 |
| ST2414835 |
| TC-162355 |
| UNII-S915P5499N |
| YIQPUIGJQJDJOS-UHFFFAOYSA-N |
| Z2196779619 |
| ZINC22443609 |
US Patents and Regulatory Information for MOZOBIL
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Genzyme | MOZOBIL | plerixafor | SOLUTION;SUBCUTANEOUS | 022311-001 | Dec 15, 2008 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| Genzyme | MOZOBIL | plerixafor | SOLUTION;SUBCUTANEOUS | 022311-001 | Dec 15, 2008 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for MOZOBIL
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Genzyme | MOZOBIL | plerixafor | SOLUTION;SUBCUTANEOUS | 022311-001 | Dec 15, 2008 | Start Trial | Start Trial |
| Genzyme | MOZOBIL | plerixafor | SOLUTION;SUBCUTANEOUS | 022311-001 | Dec 15, 2008 | Start Trial | Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for MOZOBIL
| Drugname | Dosage | Strength | RLD | Date |
|---|---|---|---|---|
| ➤ Subscribe | Injection | 24 mg/1.2 mL vials (20 mg/mL) | ➤ Subscribe | Start Trial |
International Patents for MOZOBIL
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Mexico | PA04000982 | Start Trial |
| Spain | 2380009 | Start Trial |
| Israel | 159312 | Start Trial |
| China | 102302493 | Start Trial |
| Brazil | 0211570 | Start Trial |
| Netherlands | 300537 | Start Trial |
| South Korea | 20090130152 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for MOZOBIL
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1411918 | C20120014 00064 | Estonia | Start Trial | PRODUCT NAME: MOZOBIL - PLERIXAFOR;REG NO/DATE: C(2009)6238 31.07.2009 |
| 1411918 | PA2012011 | Lithuania | Start Trial | PRODUCT NAME: PLERIXAFORUM; REGISTRATION NO/DATE: EU/1/09/537/001 20090731 |
| 1411918 | SPC/GB12/031 | United Kingdom | Start Trial | PRODUCT NAME: PLERIXAFOR OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT OR METAL COMPLEX THEREOF; REGISTERED: UK EU/1/09/537/001 20090804 |
| 0619813 | C300425 | Netherlands | Start Trial | PRODUCT NAME: PLERIXAFOR, DESGEWENST IN DE VORM VAN EEN NIET-TOXISCH ZUURADDITIE ZOUT OF METAALCOMPLEX; REGISTRATION NO/DATE: EU/1/09/537/001 20090731 |
| 1411918 | 300537 | Netherlands | Start Trial | PRODUCT NAME: PLERIXAFOR, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT OF METAALCOMPLEX; REGISTRATION NO/DATE: EU/1/09/537/001 20090804 |
| 1411918 | 2012C/027 | Belgium | Start Trial | PRODUCT NAME: PLERIXAFOR SOUS TOUTES FORMES COUVERTES PAR LE BREVET DE BASE; AUTHORISATION NUMBER AND DATE: EU/1/09/537/001 20090804 |
| 1411918 | 122012000044 | Germany | Start Trial | PRODUCT NAME: PLERIXAFOR ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ ODER EIN METALLKOMPLEX DAVON; REGISTRATION NO/DATE: EU/1/09/537/001 20090731 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
